FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average t	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

McCart (Last) C/O CYT	thy Sean (F				- <u>Cy</u>	2. Issuer Name and Ticker or Trading Symbol CytomX Therapeutics, Inc. [CTMX] 3. Date of Earliest Transaction (Month/Day/Year) 08/11/2021								Relationship of Reporting Person(s) to Issuer eck all applicable) X Director 10% Owner X Officer (give title Other (specibelow) President and CEO				wner (specify
(Street) SOUTH FRANCI (City)	SCO		94080 (Zip)		4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				action	tion 2A. Deemed Execution Date,		3. Transa Code (8)	4. Securities Acquired (A) action Disposed Of (D) (Instr. 3, 4		(A) or	5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D)	Price	Transacti (Instr. 3 a	on(s)			(111501. 4)
Common Stock 08/11/2					/2021	2021		М		92,113	A	\$1.133	99,922(1)			D		
Common Stock												93,158(1)				See footnote ⁽²⁾		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reporter Transact (Instr. 4)	ve es ally ig d tion(s)	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$1.1339	08/11/2021			M ⁽³⁾			92,113	(4)		09/20/2021	Common Stock	92,113	\$0.00	0		D	

Explanation of Responses:

- $1.\ Amount of securities held has been adjusted to reflect the transfer of 40 shares previously owned directly to Sean A.\ McCarthy 2018\ Trust.$
- 2. Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.
- 3. Exercise of September 2021 expiring stock options with cash.
- $4.\ 100\%$ of the shares subject to the option are fully vested and exercisable.

/s/ Lloyd Rowland, as 08/13/2021 Attorney-in-Fact for Sean A. **McCarthy**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.